### 16149 Federal Register / Vol. 75, No. 61 / Wednesday, March 31, 2010 / Notices

5630 Fishers Lane, rm. 1093), Rockville, MD 20857, 301–827–7001, FAX: 301– 827–6776, e-mail: minh.doan@fda.hhs.gov, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 3014512530. Please call the Information Line for up-to-date information on this meeting. A notice in the Federal Register about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the agency’s Web site and call the appropriate advisory committee hot line/phone line to learn about possible modifications before coming to the meeting.

Agenda : On April 29, 2010, the committee will discuss the efficacy and safety of new drug application (NDA) 21–242, artesunate rectal suppositories, submitted by the World Health Organization, for the proposed use as a single dose for the initial treatment of patients with acute malaria who cannot take medication by mouth and for whom injectable treatment is not available.

FDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA’s Web site after the meeting. Background material is available at http://www.fda.gov/ AdvisoryCommittees/Calendar/ default.htm . Scroll down to the appropriate advisory committee link.

Procedure : Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person on or before April 15, 2010. Oral presentations from the public will be scheduled between approximately 1 p.m. to 2 p.m. Those desiring to make formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before April 7, 2010. Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. The contact person will notify interested persons regarding their request to speak by April 8, 2010.

Persons attending FDA’s advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets.

FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Minh Doan at least 7 days in advance of the meeting.

FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our Web site at http://www.fda.gov/Advisory Committees/AboutAdvisoryCommittees/ ucm111462.htm for procedures on public conduct during advisory committee meetings.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: March 25, 2010. Jill Hartzler Warner, Acting Associate Commissioner for Special Medical Programs.
[FR Doc. 2010–7113 Filed 3–30–10; 8:45 am]

**BILLING CODE 4160–01–S**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES** 

**Agency for Healthcare Research and Quality** 

**Notice Of Amendment—OS ARRA Expansion of Research Capabilities To**  **Study CE Complex Patients (R24) SEP Meeting** 

With this correction notice, the Agency for Healthcare Research and Quality (AHRQ) informs the public of an amendment made to the notice subject mentioned above published on March 18, 2010 Vol. 75, No. 52, Second paragraph of pages 13 135–13136.

The revised should read: ‘‘DATE: April 15–16, 2010 (Open on April 15 from 8 a.m. to 8:15 am. and closed for the remainder of the meeting) ’’

.

Dated: March 19, 2010. Carolyn M. Clancy,

Director.
[FR Doc. 2010–6784 Filed 3–30–10; 8:45 am]

**BILLING CODE 4160–90–M DEPARTMENT OF HEALTH AND**  **HUMAN SERVICES**

**Centers for Medicare & Medicaid Services** 

**[CMS–2312–N]**

**DEPARTMENT OF LABOR**

**Employee Benefits Security Administration** 

**Medicaid and CHIP Programs; Meeting of the CHIP Working Group—April 26,**  **2010**

**AGENCIES :**  Centers for Medicare & Medicaid Services (CMS), Department of Health and Human Services (DHHS); Employee Benefits Security Administration (EBSA), Department of Labor (DOL).

**ACTION :**  Notice.

**SUMMARY :**  This notice announces the first meeting of the Medicaid, Children’s Health Insurance Program ( ‘‘CHIP ’’ ), and Employer-Sponsored Coverage Coordination Working Group (referred to as the ‘‘ CHIP Working Group ’’ ). The CHIP Working Group will meet to address objectives specified under section 311(b)(1)(C) of the Children’s Health Insurance Program Reauthorization Act of 2009. This meeting is open to the public.

**DATES :**  Meeting Date: Monday, April 26, 2010 from 9 a.m. to 5 p.m., Eastern Standard Time (E.S.T.).

Deadline for Registration without Oral Presentation: April 21, 2010, 12 p.m., E.S.T.

Deadline for Registration of Oral Presentations: April 12, 2010 12 p.m., E.S.T.

Deadline for Submission of Oral Remarks and Written Comments: April 12, 2010 12 p.m., E.S.T.

Deadline for Requesting Special Accommodations: April 12, 2010 12 p.m., E.S.T.

**ADDRESSES :**  Meeting Location: The meeting will be held at the Omni Shoreham, 2500 Calvert Street, NW. at Connecticut Avenue in Washington, DC
20008.

Submission of Testimony: Testimonies should be mailed to Stacey Green, Designated Federal Official (DFO), Centers for Medicare & Medicaid Services, 7500 Security Boulevard, Mail stop C2–04–04, Baltimore, MD 21244– 1850, or contact the DFO via e-mail at stacey.green@cms.hhs.gov.

**FOR FURTHER INFORMATION CONTACT :**  Stacey Green, DFO, Centers for Medicare & Medicaid Services, DHHS at (410) 786–6102, or Amy Turner,